Advances in Senolytic

A senolytic (from the words senescence and -lytic, "decomposition or breakdown") is among a class of small molecules under basic research to determine if they can selectively induce death of senescent cells and improve health in humans. A goal of this research is to discover or develop agents to delay, prevent, alleviate, or reverse age-related diseases. Removal of senescent cells with senolytics has been proposed as a method of enhancing immunity during aging.

In the present book, twelve typical literatures about senolytic published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on senolytic. We hope this book can demonstrate advances in senolytic as well as give references to the researchers, students and other related people.

Sample Chapter(s)
Preface (178 KB)
Components of the Book:
  • Chapter 1
    Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
  • Chapter 2
    Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery
  • Chapter 3
    Senolytic therapies for cardiovascular aging: tackling fibrosis and metabolic dysfunction
  • Chapter 4
    Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease
  • Chapter 5
    The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells
  • Chapter 6
    Current senolytics: Mode of action, efficacy and limitations, and their future
  • Chapter 7
    Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence
  • Chapter 8
    Targeted delivery of liposomal senolytics to alleviate cellular senescence-induced bone loss
  • Chapter 9
    Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
  • Chapter 10
    Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer
  • Chapter 11
    DYRK1B inhibition exerts senolytic effects on endothelial cells and rescues endothelial dysfunctions
  • Chapter 12
    Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
Readership: Students, academics, teachers and other people attending or interested in senolytic.
Sandra Atlante
Laboratory of Epigenetics, Istituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy

Valentina R. Garbarino
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Juan Pablo Palavicini
Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, USA

and more...
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top